No ratings yet
Taught by or worked with Paola? Your rating helps other students choose.
Paola Neri, MD, PhD, is an Associate Professor of Medicine and attending physician in the Hematology division at the University of Calgary, where she is also a member of the Arnie Charbonneau Cancer Institute. Since January 2019, she has served as Scientific Director of the Precision Oncology Hub, Translational Research Laboratory, at the Tom Baker Cancer Centre in Calgary. Dr. Neri received her medical degree from Magna Græcia University in Catanzaro, Italy, in 2000. She completed her specialty in Medical Oncology at the same institution in 2005 and earned a PhD in Molecular Oncology and Experimental Immunology in 2011. From 2003 to 2006, she was a Research Associate at the Dana-Farber Cancer Institute, Harvard Medical School, in Boston, under the mentorship of Dr. Kenneth Anderson. She joined the University of Calgary in June 2008.
The main focus of Dr. Neri’s research is multiple myeloma, with particular interest in drug development and genomic studies aimed at discovering novel therapeutic targets for this disease. She has investigated genome signatures associated with multiple myeloma cell response or resistance to anti-multiple myeloma agents to identify druggable therapeutic targets and new biomarkers of response to novel agents. Dr. Neri is well published in the field and has received national and international grants from agencies including the International Myeloma Society, Leukemia and Lymphoma Society, Multiple Myeloma Research Foundation, and Canadian Institutes of Health Research. In 2019, she received the Engineered Air Chair in Cancer Research from the University of Calgary. In 2021, she was selected by the International Myeloma Society to receive the Ken Anderson Young Investigator Award for her translational work in multiple myeloma. She is a member of the American Society of Hematology, co-chair of the Charbonneau Research & Innovation Committee, and a member of the Blood Editorial Board. Dr. Neri remains active in both preclinical and clinical trial research in myeloma.
Professional Email: null
Explore the groundbreaking University of Calgary study revealing resistance mechanisms to GPRC5D immunotherapy in multiple myeloma, using Canada's largest relapsed patient cohort. Implications for future treatments.
Photo by Antoine Dautry on Unsplash
Photo by Chris Liverani on Unsplash
Photo by Peter Burdon on Unsplash
Photo by Andrii Zhuk on Unsplash
Photo by EESOFUFFZICH on Unsplash
Photo by Google DeepMind on Unsplash
Photo by Gabriele Malaspina on Unsplash
